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Summary 
The rapamycin-sensitive signaling pathway is required 
to transduce specific mitogenic signals to the cell cy 
cle machinery responsible for Gl progression. Genetic 
studies in yeast identified two related genes on this 
pathway, TOR7 and TOR2, thought to encode novel 
phosphatidylinositol kinases. We now show that an 
intact kinase domain Is required for the Gl cell cycle 
functions of both proteins, for the ability of a mutation 
in a neighboring FKBP12-rapamycin-binding domain 
of the TORl protein to inhibit the growth of yeast cells 
when overexpressed, and for the essential function of 
the TOR2 protein. The Gl function of both TOR pro- 
teins is sensitive to rapamycin, but the essential func- 
tion of TOR2 is not. Thus, FKBPlIL-rapamycin does 
not appear to inhibit the kinase activity of TOR proteins 
in a general way; instead, it may interfere selectively 
with TOR protein binding to or phosphorylation of Gl 
effecters. 
Introduction 
The bacterially deriyed immunosuppressants FK508 and 
rapamycin have proved to be useful tools for dissecting 
the signaling pathways that result in resting T cells making 
a commitment to divide (Schreiber, 1992). This process 
requires two distinct signals delivered in tandem. Signals 
emanating from the T cell receptor (TCR) render the cell 
competent for cell division by establishing a second, auto- 
crine signaling pathway involving interleukin-2 (IL-2) and 
the IL-2 receptor (IL-2R). Signals from the IL-2R commit 
the cell to a program of cell division by communicating 
with components of the cell cycle machinery necessary 
for DNA replication. Although both FK508 and rapamycin 
inhibit the ability of T cells to divide by binding to the same 
immunophilin receptor (FKBP12), the resulting complexes 
target different signaling pathways. FKBP12-FK508 inhib- 
its the TCR signaling pathway by binding to and inhibiting 
the phosphatase activity of calcineurin, one of the com- 
ponents of the TCR pathway; a second immunosuppres- 
sant-immunophilin complex, cyclosporin-cyclophilin, also 
inhibitscalcineurin (Liu et al., 1991). In contrast, FKBPIP- 
rapamycin inhibits the IL-2R signaling pathway by binding 
to a 289 kDa kinase named FRAP in humans and RAFT 
in rats (Brown et al., 1994; Sabatini et al., 1994; Chiu et 
al., 1994). In effect, the immunosuppressants have two 
protein-binding surfaces that mediate the heterodimeriza- 
tion of target proteins (immunophilins and the signaling 
proteins calcineurin and FRAP) and can, thus, be consid- 
ered as analogous to proteins such as Grb2, which hetero- 
dimerize their targets. 
Although the rapamycin-sensitive target was first exam- 
ined in T cells, it is used by many eukaryotic cells to com- 
municate changes in cell growth circumstances to the cell 
cycle machinery necessary for DNA replication. For exam- 
ple, low concentrations of rapamycin induce Gl cell cycle 
arrest in yeast. Genetic studies in the yeast Saccharo- 
myces cerevisiae identified two related genes, TO/?7 and 
TOR2, containing apparent open reading frames encoding 
2470 amino acids and 2474 amino acids, respectively 
(Heitman et al., 1991; Cafferkey et al., 1993; Kunz et al., 
1993; Helliwell et al., 1994). The highest degree of similar- 
ity, with over 80% amino acid identity, resides in their 
C-termini, which are related to the catalytic domains of 
phosphatidylinositol (PI) kinases. This C-terminal kinase 
domain is interchangeable between TOR7 and TOR2, sug- 
gesting they have similar functions (Helliwell et al., 1994). 
That the proteins themselves have distinct functions is 
evident from studies of the for7 null mutant, which has 
only a partial growth defect under normal growth condi- 
tions, and the for2 null, which has a lethal phenotype with 
cells arrested randomly in the cell cycle. Like treatment 
with rapamycin, the for7 tor2 double disruption results in 
Gl arrest (Kunz et al., 1993; Helliwell et al., 1994). When 
the conserved serine residues, Ser-1972 in 7OR7 and Ser- 
1975 in TOR2, are changed to isoleucine or arginine, either 
gene confers dominant rapamycin resistance. 
The C-terminal kinase domains in FRAP and TOR are 
more than 80% identical. The substrate(s) of these do- 
mains has not yet been identified, despite their apparent 
similarity to the PI3-kinase (Pl3K) and PICkinases (Pl4K). 
The two cloned Pl3Ks, the ~110 Pl3K in mammals and 
Vps34 in yeast, also have protein kinase activity (Dhand 
et al., 1994; Stack and Emr, 1994). Although the conse- 
quences of the two kinase activities are currently un- 
known, roles have been established for these proteins in 
several signaling pathways, including mitogenic pathways 
(for reviews see Carpenter and Cantley, 1990; Divecha 
and Irvine, 1995). 
In this study, we show that TORl binds directly to 
FKBPl2-rapamycin and that a small region surrounding 
Ser-1972, the FKBPl2-rapamycin-binding (FRB) domain, 
is sufficient for mediating this interaction. Substitution of 
Ser-1972 with residues larger than serine abolish this inter- 
action both in vivo and in vitro and confer dominant rapa- 
mycin resistance, although substitution with alanine does 
not. Genetic analyses indicate that the kinase domains in 
both TOR proteins are required for their rapamycin- 
sensitive Gl functions. Point mutations that inactivate 
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known PI and protein kinases (kinasedead mutations) 
were found to abolish the ability of the TOR mutants at 
Ser-1972 (TOM) and Ser-1975 (TOR2) to allow growth in 
the presence of rapamycin and to abolish the ability of 
one of these, TORl (Ser-1972+le), to produce a unique, 
dominant cell growth inhibitory phenotype when overpro- 
duced. Furthermore, overproduction of a TOR kinase- 
dead mutant causes Gl cell cycle arrest. These results 
establish that the kinase domains of TOR proteins are 
essential for Gl cell cycle progression in yeast. We also 
show that a function of TOR2 that is required for cell viabil- 
ity, the essential function, is dependent on a functional 
TOR kinasedomain. This essential function is nonetheless 
resistant to the actions of rapamycin, in contrast with its 
Gl function. The results suggest that FKBPl2-rapamycin 
may interfere with the binding or phosphorylation of Gl 
effecters only, rather than inhibit the kinase activity of TOR 
proteins in a general way. These studies indicate that the 
TOR/FRAP proteins define a novel family of kinases and 
that the kinase domains of these proteins are essential 
for their cellular functions. 
Results 
TOM Binds to Yeast FKBPlP-Rapamycin 
Both In Vivo and In Vitro 
Two mammalian homologs of TOR proteins, FRAP and 
RAFT, have recently been purified using FKBPl2-rapa- 
mycin affinity matrices (Brown et al., 1994; Sabatini et 
al., 1994). We have used a similar strategy to examine 
whether TORl and TOR2 proteins bind directly to the 
yeast FKBPlP (yFKBPlP)-rapamycin (using glutathione 
S-transferase [GSTj-yFKBP12 fusion protein complexed 
to rapamycin; yGFK-rapamycin) complex. A single, ap- 
parently low abundance polypeptide of M, 220,999 from 
crude yeast lysates was specifically retained on a yGFK- 
rapamycin column, but not to yGFK-FK506 or yGFK alone 
(Figure 1A). The gel mobility of the yeast protein is similar 
to that of human FRAP (Brown et al., 1994) suggesting 
the proteins are related. Indeed, the 220 kDa protein was 
recognized specifically by an anti-TORl immune serum, 
but not the preimmune serum on a Western blot (Figure 
1B). We generated yeast mutants carrying the chromo- 
somal mutations Ser-1972+Arg in TO/W or Ser-1975wArg 
in TOR2 by homologous recombination. The Ser-1972 mu- 
tation in TORl abolished the binding of this protein to 
yGFK-rapamycin in two independent mutant strains, while 
no effect was observed with the TOR2 mutant strains (Fig- 
ure 1C). Thus, the 229 kDa protein purified by yGFK- 
rapamycin appears to be TORl , and mutation at Ser-1972 
prevents its binding to yFKBPlP-rapamycin. Since a 
TOR2 fragment has been shown to bind to FKBP12-rapa- 
mycin in a yeast two-hybrid assay (Stan et al., 1994) TOR2 
most likely also binds; our inability to detect such binding 
in the TORl mutant strains may be due to its low level of 
expression. 
Deletional analyses using an in vitro transcription-trans- 
lation system (rabbit reticulocyte lysates) indicate that 
TORl with a C-terminal truncation up to amino acid 2157 
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Figure 1. TORI Binds Directly to FKBPlP-Rapamycin Complex 
(A and B) S. cerevisiae yeast lysates were applied to a Mono0 column. 
After extensive washing, samples were eiuted with 1 M NaCI. The 
eluants were incubated with 0.7 pM yGFK alone, yGFK-FK599, or 
yGFK-rapamycin and were allowed to bind to a gtutathione S-Sepharose 
(GTS) column. The GTS-bound material was washed, eluted into SDS 
gel sample buffer, separated by7.5% (A, top, and S)or 2o% (A, bottom) 
SDS-polyacrylamide gel electrphoresis, and analyzed by silver stain- 
ing (A), by immunoblot with anti-TORI immune serum (B, top) or with 
preimmune serum (6. bottom) as a control. 
(C) TORl (Ser-1972+Arg) does not bind to an FKBPlP-rapamycin 
complex. The following haploid yeast strains were used for the yGFK- 
rapamycin binding assay: wild type (MATa, TO/V, TOR2), two indepen- 
dent clones (TOR7-7 and TOM-2) of the mutant (MATa, TOP7 [Ser- 
1972*Arg], TOR2), and two independent clones (TOR2-1 and TOff2- 
12) of the mutant (MATa, TOR7, TOP2 [Ser-1975+Arg]). The purifica- 
tion procedure is the same as Figure IA. The final yGFK- or yGFK- 
rapamycin-bound materials were analyzed by silver staining. 
is able to bind to yGFK-rapamycin. A further removal of 
21 amino acids abolishes this binding (Figure 2A). We 
found a 45 kDa fragment of TORl (TORl-45, amino acids 
1775-2157) containing Ser-1972 was sufficient to bind to 
yGFK-rapamycin. Two naturally selected dominant rapa- 
mycin-resistant mutations at Ser.1 972, arginine and iso- 
leucine, disrupt yGFK-rapamycin interaction wfth TOR145 
completely. Similarly, glutamic acid, a residue potentially 
analogous to phosphoserine, also abolishes the ability of 
TOR1-45 to bind yGFK-rapamycin. In contrast, alanine, 
a potential mimic of unphosphorylated serine, does not 
affect yGFK-rapamycin binding (Figure 28). 
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Figure 2. Mapping FRB Domain in TORl 
(A) A series of “S-labeled TORI deletional mutants was generated in 
vitro, incubated with 0.7 PM yGFK or yGFK-rapamycin, and purified 
onto GTS columns. The GTS-bound materials were eluted into SDS 
protein gel sample buffer, separated on SDS protein gels, and ana- 
lyzed by X-ray autoradiography. Bars indicate different truncated 
TORI s. Plus indicates TORl fragments that bind to yGFK-rapamycin; 
minus indicates TORl domains that do not bind to yGFK-rapamycin. 
(B) Assay for the effects of substitutions at Ser-1972 on the binding 
of TORl to FKBPlP-rapamycin. The abilii of %-labeled wild-type 
TOR1-45, or Ser-1972+Ala, Ser-1972+Glu, Ser-1972+lle, and Ser- 
1972+Arg mutant TOR1-45 (FRB domain) to bind yGFK or yGFK- 
rapamycin wasassayed similarly to (A). Total indicates total %-labeled 
TOR145 FRB used. S, wild-type Ser-1972; A, Ala-i 972; E, Glu-1972; 
I, 118-1972; R, Arg-1972. 
(C) Overexpression of FRB domain of TORl allows yeast to resist 
rapamycin. S. cerevisiae EGY43 (Gyuris et al., 1993) expressing the 
Cells expressing the Ser-1972+Arg, Ser-1972-116, and 
the Ser-1972+Glu mutants, which fail to bind to FKBP12- 
rapamycin, were able to resist rapamycin (Table 1). In con- 
trast, the Ser-1972eAla mutant, which retains the ability 
to bind FKBPlP-rapamycin, was unable to confer resis- 
tance to rapamycin. When the FRB domain-containing 
TOR145 is overproduced, yeast cells were able to grow 
normally in 100 nM rapamycin, a concentration at which 
the growth of normal yeast cells is completely inhibited 
(Figure 2C). In contrast, cells expressing TOR145 (Ser- 
1972-Arg), a mutant that does not bind yGFK-rapamycin 
in vitro, are sensitive to rapamycin (Figure 2C). Thus, these 
in vivo assays for the interaction between FKBP12-rapa- 
mycin and TORl confirm the results obtained in the in 
vitro biochemical experiments and suggest that TORl 
binding to FKBP12-rapamycin occurs in vivo. 
The Kinase Domains in TORl and TOR2 Are 
Essential for Their Gl Functions 
Because of their sequence similarity with other PI kinases, 
proteins of the TORlFRAP family were anticipated to have 
PI kinase activities. Thus far, we have tested in vitro kinase 
activities of recombinant TORl proteins produced in yeast 
and E. coli and FRAP proteins expressed in E. coli and 
mammalian and Sf9 cells toward PI, PI phosphate deriva- 
tives, and several other potential lipid substrates. We have 
been unable to demonstrate any such activity with TORl 
or FRAP proteins. We also carried out HPLC analyses of 
total cellular PI phosphate products, using in vivo PH]inosi- 
tol labeling, following rapamycin treatment or overexpres- 
sion of TORl proteins. Nosignificant alterations in PI phos- 
phate products were observed (X.-F. Z., P. A. Beal, and 
S. L. S., unpublished data). Since Pl3K and Vps34 were 
previously shown to exhibit protein kinase activity, we also 
examined whether TORl and FRAP have intrinsic protein 
kinase activity. To facilitate this analysis, we introduced 
two kinase inactivation substitutions, Arg-2276+Pro and 
Asp-2294*Glu, into the wild-type TOR7 and Ser-1972 
TO/?7 dominant rapamycin-resistant mutants. The analo- 
gous kinase-dead mutations were shown previously to 
abolish the activities of Pl3K and Vps34, respectively (Schu 
et al., 1993; Dhand et al., 1994), and we have shown that 
similar mutations in FRAP abolish a serine-autophos- 
phorylation activity in wild-type FRAP and its Ser-2035 
(corresponding to Ser-1972 in TORl) mutant expressed 
in mammalian (E. J. Brown, P. A. Beal, J. Chen, T.-B. 
Shin, and S. L. S., unpublished data) and Sf9 cells (P. A. 
Beal, C. Keith, and S. L. S., unpublished data). However, 
we have not been able to obtain conclusive biochemical 
evidence for a protein kinase activity in wild-type TORl 
expressed in yeast cells. It is possible that the autophos- 
TOR145 FRBdomain was assayed for rapamycin sensitivity. TOR1-45 
(FRB) expression is under the control of the GAL1 promoter (GAL, 2 
PM. MA). Yeast cells were streaked onto uracildropout plates con- 
taining glucose or galactose supplemented with or without 100 nM 
rapamycin, and incubated at 30% for 3 days. Rapamycin resistance 
was scored by the ability of the cells to form colonies. A, control; 8, 
wild-type TOR1-45 (FRB); C, Ser-1972+Arg mutant TOR145 (FRB). 
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Table 1. Effect of Mutations on TORl 
Mutation 
Ser-1972 (wt) 
Ser-1972 Arg-2276-Pro 
Ser-1972 Asp2294-Glu 
Ser-1972-Ala 
Ser-1972+Arg 
Ser-1972+ArglArg-2276+Pro 
Ser-1972+Arg/Asp2294+Glu 
Ser-1972-rGlu 
Ser-1972+Glu/Arg-2276+Pro 
Ser-1972+Glu/Asp-2294+Glu 
Ser-1972~lie 
Ser-1972+lle/Arg-2276+Pro 
Ser-1972+lle/Asp-2294+Glu 
ND, not determined. 
GFK-Rap Binding 
Yes 
ND 
ND 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Rapamycin Resistance 
No 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
Complementation of Temperature 
Sensitivity of Atorl 
Yes 
ND 
ND 
Yes 
ND 
ND 
ND 
ND 
ND 
ND 
Yes 
ND 
ND 
phorylation site on TORl does not exist or that the condi- 
tions for yeast cell lysis are too harsh to preserve this 
activity. By taking a genetic approach, we have succeeded 
in revealing the importance of the kinase domains in TOR 
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Figure 3. Kinase Domains Are Essential for Rapamycin-Sensitive Gl 
Functions of TORI and TOR2 
(A) S. cerevisiae BJ6469 expressing wild-type or mutant TORl proteins 
under the control of the gafactose-inducible promoter (GAL, 2 pM, 
TRP) were assayed for their sensitivity to 100 nM rapamycin as in 
Figure X. A, control; 8, wild-type TORl; C. TORl (Ber-1972+lle); D, 
TORl (Ser-1972~lle/Arg2276+Pro); E, TORI (Ser-1972Me/Asp- 
2294~Giu). 
(B) BJ6469 expressing TORZ or TOR2-TOW wild-type and mutant 
genes (ARSUXN, LEU) were asseyed for their sensttttity to 166 nM 
rapamyctn. A, TOR2; 8, TCR2-TORI; C, TOf?2-TORl (Ser-197Wlte); 
D, TOR2-TORI (Ser-1972+lle/Arg2276+Pro); E, TORP-TORI (Ser- 
1972-+e/Asp-2294+Glu). 
proteins, and we find that the cellular effect of the muta- 
tions discussed above correlate precisely with their effect 
on the protein kinase activity observed with FRAP. Both 
TORl kinasedead mutations abolish the ability of the Ser- 
1972+lle mutant to confer dominant rapamycin resistance 
when the double mutants (Ser-1972+lle/Arg-22764Pro 
and Ser-1972+lle/Asp2294+Glu) were expressed at low 
levels in glucose medium (Figure 3A). Similar effects were 
also seen with the Ser-1972+Glu and the Ser-1972+Arg 
double mutants (Table 1). It was previously established 
that the C-terminus of both 7OR7 and TOR2 are function- 
atly interchangeable (Hetfffll et al., 1994). We engineered 
chimeric TOR proteins comprising the N-terminus of 
TOR2 and C-terminus of TORl. The wild-type chimeric 
TORP-TORl protein (CEN4, LEU) complements the for2 
null strain, showing that it is an active and functional pro- 
tein and confirming the earlier report(Helliwell et al., 1994; 
see Figure 6). However, the two kinasedead mutations 
abolish the ability of the serine TOR2 mutant to resist the 
actions of rapamycin (Figure 36). 
Kinasedead mutants of protein kinases often exhibit a 
dominant negative effect on growth by interacting in a 
nonproductive way with effector proteins normally associ- 
ating with the wild-type kinase. We found that the Arg- 
2276ePro and the Asp-2294-01~ TORI mutants, when 
overproduced following gala&se induction, inhibii growth 
of yeast cells cultured on solid (but not liquid) medium as 
shown in Figure 4; ffow cytometric analysis revealed these 
cells undergo Gl cell cycle arrest (data not shown). This 
observatii indicates that the kinasedead TORl proteins 
exhibit a dominant negative effect on TORl function. 
Since the tori null mutation alone does not cause Gl ar- 
rest, the dominant negative TORI mutants must interfere 
with the Gl functions of both TOR proteins. 
An Intact Kinase Domain Is Also Required for the 
Ser-1972-Ne Mutatlon in TORl to lnhlbit Cell 
Growth Oomirmtly 
When tested for rapamycin sensitivity under galactose in- 
duction, the TORl (Ser-1972+lle) mutant prevented growth 
of yeast cells in a rapamycin-independent manner, even 
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Figure 4. Overexpression of TOM Kinase-Dead Mutants Cause Gl 
Cell Cycle Arrest 
S. cerevisiae SJ5459 expressing wild-type or mutant TORl proteins 
under the control of the GAL7 promoter (GAL, 2 uM, TRP) were assayed 
for their ability to grow on glucose or galactose media. A, control; B, the 
wild-type TOW; C, TORl (Arg-2276-tPro); D, TORI (Asp2294*Glu). 
though its low level of expression in the presence of glu- 
cose is sufficient to resist rapamycin. in liquid culture, 
yeast cells overexpressing the wild-type TORl protein or 
its Ser-1972eAla mutant have a normal growth rate that 
is comparable to that of yeast cells carrying a control vector 
(Figure 5). In contrast, the growth of yeast ceils overex- 
pressing the TOFU (Ser-1972*lle) protein was signifi- 
cantly diminished. This dominant growth-arresting effect is 
dependent upon the existance of an intact kinase domain. 
When the kinase-inactivating mutations Arg-2276+Pro or 
Asp2294+Glu were introduced into TORl (Ser-1972+le), 
the dominant growth inhibitory effect of the Ser-1972~lie 
mutation was lost (Figure 5). This difference in growth inhi- 
bition is not due to a higher level of TOR protein expression 
by the TORl (Ser-1972+lle)-expressing cells, as judged 
by Western blots (data not shown). This growth-arresting 
phenotype of the TOR7 (Ser-1972-118) allele is clearly dif- 
ferent from the dominant negative effects seen with ki- 
nase-dead TORl mutants. The TORI (Ser-1972+lle) mu- 
tant allele appears to preserve all the normal function of 
wild-type TOR, as evidenced by its ability to resist the ac- 
tions of rapamycin and by its ability to complement the 
tor2 null as a chimeric protein with a TOR2 N-terminus. In 
addition, the dominant negative effect of the kinase-dead 
TORI mutants is seen only on solid medium. In contrast, 
overexpression of TORl (Ser-1972-,lle) causes cell 
growth arrest in both liquid (Figure 5) and solid (data not 
shown) cultures. The effects of overexpression of TORl 
(Ser-1972*lle) mutant on cell cycle progression and check- 
points are currently under investigation. 
TOFU Has an Essential Function That Is Not 
Inhibitable by FKBP12-Rapamycin 
To investigate whether the function of TOR2 is sensitive 
to the actions of rapamycin, we engineered a tori null 
strain by inserting a LEU2 marker into the Bamlil site of 
TOR7 gene in the kinase domain (Figure 6A). This insertion 
has been shown previously to knock out the function of 
the TOR7 gene (Kunz et al., 1993; Helliwell et al., 1994). 
The Ator7 strain was found to undergo Gl cell cycle arrest 
when treated with rapamycin, indicating that the TOR2 
protein is a target of the actions of rapamycin in vivo (Fig- 
ure 6A). Despite the fact that a tor2 disruption in a wild-type 
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Figure 5. Dominant Growth Arrest by Overexpression of TORl (Ser- 
1972elle) Is Dependent on an Intact Kinase Domain 
Yeast cells expressing wild-type or mutant TORl proteins under the 
control of galactose-inducible promoter (GAL, 2 PM, TRP) were as- 
sayed for their ability to grow under conditions of galactose induction. 
The overnight yeast cultures in glucose were diluted into sucrose me- 
dia at OD, = 0.25 and were incubated for 4 hr at 30%. The cells 
were harvested bycentrifugation, resuspended intogalactose medium 
at ODem = 0.25, and incubated at 30%. Aliquots of cultures were 
withdrawn at different times for OD measurement at 666 nM. 
TOR7 background is lethal, the TO/?7 (Ser-1972-Arg) mu- 
tant allele allows yeast to grow in the presence of rapa- 
mycin. These observations suggest that if rapamycin in- 
hibits all functions of TOR2, then the TORl (Ser-1972-+Arg) 
mutant, but not the wild-type TORI, causes a gain of TORl 
function that should complement the for2 null lethal pheno- 
type. We tested this by disrupting the TOR2 gene either 
in a wild-type TOR7 or a TO/37 (Ser-1972*Arg) mutant 
background (Figure 6B). First, diploid heterozygous TO/W 
for2 mutants in either a wild-type TOR7i7OR7 or mutant 
homozygous TOR7SRITORl SR background were gener- 
ated by inserting a LEU2 marker into the BamHI site in 
the kinase domain previously shown to inactivate the 
TOR2 gene (Helliwell et al., 1994). Tetrad analyses 
showed that in both genetic backgrounds, only two or less 
viable spores (versus four) were obtained (Figure 68). 
None of the viable spores were found to cosegregate with 
the LEUP marker, indicating that in either genetic back- 
ground, the for2 disruption is lethal. This result demon- 
strates that the TORl (Ser-1972+Arg) mutation does not 
complement the lossof theTOR2essentialfunction. Given 
the dominant rapamycin-resistant phenotype of this TORl 
mutation and the sensitivity of TOR2 to rapamycin, we 
conclude that the essential function of TOR2, in contrast 
with its Gl function, is not inhibited by FKBP12-rapa- 
mycin. This is consistent with the observation that treating 
the tori null strain described above with rapamycin re- 
sulted in Gl cell cycle arrest, which is in contrast with the 
random cell cycle arrest phenotype observed with the tor2 
null strain. 
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Figure 6. TOR2 Has an Essential Function That Is Not Sensitive to 
Rapamycin 
TORI or TOP2 gene was disrupted by insertion of a marker gene into 
the conserved SamHI site. The small arrows indicate PCR primers for 
analyzing the disruption results. The small bar shows the TORI or 
TOR2 sequence used for making the disruption constructs. 
(A) Yeast cells lacking TOM are still sensitive to rapamycin. Haploid 
wild-type or tor7 null yeast cells were assayed for sensitivity to 196 
nM rapamycin. A, wild-type yeast (MATa, TORI, TOR2); 6, mutant 
yeast (MATa. TOR7 [Ser-1972+Arg], TO&); C and D, two clones of 
tori disrupted strains (MATa, torl::LEU, 7DR2). 
(8) TORI (Ser-1972+Arg) does not complement lethality associated 
with TOFt2 disruption. Dipbkl yeast heterozygous for TOR2 disruption 
in a wild-type TORI background (MATa/a, TOR7/TOR1, TOFt2Ror2d:: 
LEU) or a Ser-i97&Arg mutant TOFU background (MATala, TORI 
[Ser-1972+Arg]/TORI [Ser-1972+Arg], TORMor2::LEU) were al- 
lowed to sporulate. Tetrads were dissected, and viable spores were 
grown into colonies. In either genetic background, tetrad analyses 
always show a 2:2 or a 16 segregation of viable versus nonviable 
spores. 
(C) The kinase domain is required for the essential function of TOf?2. 
Diptotd yeast cells carrytng a heterozygous TOR2 disruption (TORY 
tor2dMG-URA-H/SO) and plasmid-born wild-type and mutant TOR2 
or TOR2-TOR7 fusion genes (L/X/2, ARSAXN) under the endogenous 
TOR2 promoter were sporulated. Dissected spores were grown on 
YPD plates, from which replica Et/- or URAdmpout plates were made. 
Viable spores were counted with URA marker from a total of viable 
Since the specificity of the essential function of TOFt2 
is determined by its N-terminus (Helliwell et al., 1994), we 
asked whether this essential function requires a functional 
kinase domain. We established diploid yeast strains with 
a heterozygous insertion of a URA marker into the BamHl 
site of the TOR2 gene (TOR2/?or2). Piasmids expressing 
extrachromosomal (CEN4, LEU2) TOR2, TOR2-TOM, 
TOR2-TORl(SI), TORP-TORl(DE), TOR2-TORl(SI/DE) 
were then introduced into the heterozygotes. After sporu- 
lation, we examined how the LEU2 and URA markers asso- 
ciate in the viable spores. Of the - 40 viable spores show- 
ing LEU2 prototrophy for each strain, half were found to 
have the URA marker for cells expressing TOR2, TOR2- 
TORl, and TOR2-TORl(SI), but none were found to have 
the URA marker with cells expressing the kinase-dead 
TOR proteins (Figure 6C). Thus, the essential function of 
TOR2 requires a functional kinase domain. 
Discussion 
TOR7 (or DRR 7) and TORP(or DRR2) genes were originally 
isolated as mutations at a conserved residue, Ser-1972 
in TORl or Ser-1975 in TOR2, that confer a dominant 
rapamycin-resistant phenotype in yeast (Cafferkey et al., 
1993; Helliwell et al., 1994). Our results demonstrate that 
TOR proteins are direct targets of FKBPl2-rapamycin. 
TORl and TOR2 (this study) and their mammalian homo- 
logs FRAP (Brown et al., 1994) and RAFT (Sabatini et 
al., 1994) bind directly to the FKBPl P-rapamycin complex 
during in vitro purification or in a two-hybrid yeast screen- 
ing (Chiu et al., 1994). Isorapamycin, a rapamycin deriva- 
tive that binds FKBP12 with high affinity but is a poor inhibi- 
tor of cell cycle progression, binds less efficiently to both 
FRAP (Brown et al., 1994) and TORl (X.-F. Z. and S. L. 
S., unpublished data). Mutational analyses indicate that 
the conserved residues, Ser-1972 in TORl and Ser-1975 
in TOR2, are essential for interaction with FKBP12-rapa- 
mycin in both our in vivo and in vitro binding studies. The 
steric requirements for this residue are highly stringent. 
Serine and alanine are permissive for the binding of 
FKBPl2-rapamycin, whereas larger residues abolish this 
interaction. These binding results correlate well with the 
ability of mutant TOR proteins to resist the inhibitory ac- 
tions of rapamycin. Mutations that disrupt binding of 
FKBP12-rapamycin to TOR proteins confer rapamycin re- 
sistance in an in vivo assay. In contrast, the Ser-1972+Ala 
mutant, which binds FKBP12-rapamycin, is as sensitive 
to rapamycin as wild-type TORl . On the other hand, the 
gene encoding the Ser-1972+Ala mutant appears to have 
normal TOR7 function, as shown by its ability to comple- 
ment the temperature sensitivity of a tori mutant strain 
(Table 1). A small FRB domain of TORl surrounding Ser- 
1972 is suff icient for binding to the complex. When overex- 
spores carrying LEU2. Rescue of the lethality caused by TOR2 disrup- 
tion was determined by analyzing the cosegregation of the two 
markers. 
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pressed, this domain also allows cells to resist the actions 
of rapamycin, indicating that such binding occurs in vivo. 
In contrast, when the domain containing the Ser-1972+Arg 
mutation that disrupts binding to FKBPlP-rapamycin in 
vitro is overexpressed, it does not produce the rapamycin- 
resistant phenotype. Together, these results establish that 
binding to the FRB domain is essential for the Gl inhibitory 
function of FKBPlP-rapamycin and that the conserved 
serine residue is critical for this interaction. 
PI kinases and their phospholipidderived products have 
been shown to be important in a variety of cellular pro- 
cesses, including mitogenic signaling pathways (for re- 
views see Carpenter and Cantley, 1990; Divecha and Ir- 
vine, 1995). The kinase domain among TOR-related 
proteins from yeast to humans is highly conserved, show- 
ing over 60% identity between TORl and human FRAP 
in this region. However, a phylogenetic analysis reveals 
that FRAP, TO/W, TOR2, MECl/ESRl, and e2787(TELI) 
appear to constitute a third family of “lipid” kinases that 
have clearly diverged from the Pl3K and Pl4K families, 
which themselves are phylogenetically distinct from each 
other (C. Keith and S. L. S., unpublished data). Consistent 
with this analysis, we have not been able to demonstrate 
TOR- or FRAP-catalyzed phosphorylation of a variety of 
potential lipid substrates, including PI and PI phosphates, 
and lipid extracts from cells. In addition, we have not de- 
tected any change in the concentration of cellular PI phos- 
phates following rapamycin treatment of yeast cells labeled 
in vivo with [3H]inositol, or following the overexpression 
of the TORl protein. Although we have not been able to 
obtain conclusive biochemical evidence for a protein ki- 
nase activity in wild-type TORl expressed in yeast, possi- 
bly due to the harsh conditions required for the lysis of 
yeast cells, we have been able to demonstrate a serine 
autophosphorylation kinase activity in wild-type FRAP and 
Ser-2035 mutants of FRAP expressed in mammalian (E. J. 
Brown, P. A. Beal, J. Chen, T.-B. Shin, and S. L. S., unpu b- 
lished data) and Sf9 cells (P. A. Beal, C. Keith, and S. L. S., 
unpublished data). It is therefore likely that TOR proteins 
and their analogous Ser-1972/Ser-1975 mutants also have 
protein kinase activity. 
In this study, w& have taken a chemical/genetic ap- 
proach to study the role of the kinase domains in mediating 
TOR functions. Rapamycin, which causes Gl cell cycle 
arrest in yeast, has been used as a chemical equivalent 
of a loss-of-function conditional allele of TOR proteins: its 
inclusion in functional experiments results in the loss-of- 
function of endogenousTOR proteins. Since the Ser-19721 
Ser-1975 TOR mutants described above do not bind 
FKBPl P-rapamycin, they have been used in the presence 
of rapamycin to assess the functional role of TOR kinase 
domains. We find that kinasedead mutations analogous 
to those that inactivate the lipid and protein kinase activity 
of PI kinases, and the protein kinase activity of FRAP, 
abolish the ability of the dominant rapamycin-resistant mu- 
tations in both TORl and TOR2 to resist the actions of 
rapamycin. These experiments with double mutants es- 
tablish that an intact kinase domain is essential for the 
Gl functions of both TOR proteins. In addition, when over- 
expressed, the kinase-dead single mutants of TORI men- 
tioned above show a dominant negative phenotype, re- 
sulting in Gl cell cycle arrest of yeast growing on a solid 
medium. Since TORl and TOR2 appear to have redun- 
dant Gl functions, the kinasedead TORl protein may 
bind to the Gl effecters common to TORl and TOR2, 
inhibiting the action of both wild-type proteins. 
In experiments that do not rely upon the actions of rapa- 
mycin, we found that overproduced TORl (Ser-1972+lle), 
but not the wild-type or TORl (Ser-1972-+Ala) mutant pro- 
teins, dominantly inhibits cell proliferation by a mechanism 
that is also dependent upon its kinase domain (Figure 5). 
Although we have not fully characterized the resulting phe- 
notype, preliminary experiments suggest that overexpres- 
sion of this Ser-1972 mutant may interfere with the function 
of a cell cycle checkpoint (X.-F. 2. and S. L. S., unpub- 
lished data). The TORl (Ser-1972+lle) mutant appears 
to preserve the normal functions of the wild-type protein, 
as it allows cells to resist rapamycin dominantly, it sup- 
presses the temperature sensitivity of a for7 mutant (Table 
l), and its C-terminal domain (including the kinase and 
mutant FRB domains) provides the essential TOR2 func- 
tion when fused to the N-terminal domain of TOR2. Thus, 
growth inhibition is not due to a dominant negative effect. 
The growth inhibitory phenotype of the TORl (Ser- 
1972-lle) mutant may be due to the constitutive modifica- 
tion of aTOR effector, possibly due to an activating influ- 
ence of the isoleucine group on the kinase of TORl. 
Changes in the conserved serine residue may provide a 
conformational basis for kinase activation. Ser-1972 and 
its flanking sequences are found in the kinase domain of 
FRAP and TOR proteins, but not in the kinase domains 
of the known PI kinases. Thissequence may be analogous 
to ones found in the regulatory domains of the serinel 
threonine kinases PKG and PKC (these domains are also 
immediately N-terminal to the kinase domains) and the 
homologous regulatory subunits RI and RII of PKA. Stud- 
ies of these protein kinases indicate that the putatively 
analogous sequences act as inhibitory pseudosubstrates, 
interacting directly with the kinase active site. A striking 
similarity in the kinases of the FRAP/TOR family and the 
CAMP-dependent protein kinase PKA is that in both in- 
stances the key serine residue in the regulatory domain 
can be mutated to alanine without removing the binding 
properties of the domains, while mutation to larger resi- 
dues results in potent inhibition of binding (Buechler and 
Taylor, 1991). Ourobservationssuggest that Ser-1972 and 
its surrounding FRB domain may be behaving in a way that 
is analogous to the RII subunit of PKA and the N-terminal 
regulatory subunit of PKG. 
The TOR poteins are functionally and structurally re- 
lated, yet they also have distinguishing features. The C-ter- 
minal kinase domains of the TOR proteins can be inter- 
changed without loss of function (Helliwell et al., 1994), 
and certain mutations at the conserved serine in their FRB 
domains in either protein allow yeast to resist the actions 
of rapamycin dominantly. Double disruption of TON and 
TOR2 results in Gl cell cycle arrest, and as shown above, 
in both cases their Gl function requires an active kinase 
Cdl 
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domain. In addition, the dominant negative TORl kinase- 
dead mutant arrests the cell cycle in Gl , as does rapa- 
mycin. These results suggest that the kinase domains of 
both proteins share a common Gl function. But, although 
the loss of TOR7 only slightly affects yeast cell growth, 
the loss of TOR2 is lethal and results in random cell cycle 
arrest (Kunz et al., 1993). The dominant nature of the FRB 
domain mutations in TORl , which allow yeast to proliferate 
even though both endogenous TORsare inhibited by rapa- 
mycin, suggests that the mutations may lead to a gain of 
TORl function that complements the functions of TOR2. 
Although rapamycin inhibits at least the Gl function of the 
TOR2 protein as evidenced by the rapamycin sensitivity 
of a tori null strain (see above), and TOR2 is an essential 
gene, rapamycin-treated yeast harboring the TORl (Ser- 
1972+Arg) mutation do not show the tor2 null lethal phe- 
notype, suggesting specifically that the TOR7 mutation 
may suppress this phenotype. An alternative explanation 
is that rapamycin might inhibit only a subset of the func- 
tions of TOR2 and that in the presence of rapamycin its 
essential function is still intact. This is indeed suggested 
by the finding that the rapamycin-treated tofl null strain 
is observed to arrest specifically in Gl, suggesting that 
rapamycin might target only the Gl function of the TOR2 
protein and not its essential function. To test this, we stud- 
ied whether a dominant rapamycin-resistant TOR7 mutant 
could suppress the lethality of a for2 null mutation. Tetrad 
analyses with diploid yeast containing a heterozygous 
TOR2 allele (TOR2/.4for2) in either a wild-type TOR7/TOR7 
or homozygous mutant TOR7 (Ser-1972+Arg)/TOR7 (Ser- 
1972+Arg) background revealed that in either genetic 
background, the tor2 null is lethal. Thus, although rapa- 
mycin inhibits the Gl function of the TOR2 protein, it does 
not inhibit a second, essential function of the protein. We 
tested whether this TOR2 essential function requires an 
intact kinase domain by complementing the tor2 null with 
plasmid-born wild-type or kinasedead mutant TOR2- 
TO/?7 fusion genes. Only those genes with an intact kinase 
domain were able to rescue the lethality associated with 
the TOR2 disruption. Thus, this essential TOR2 function 
also requires a functional kinase domain. Since both rapa- 
mycin-sensitive and -insensitive functions of TOR2 require 
a functional kinase domain, FKBPI 2-rapamycin does not 
appear to inhibit directly the kinase activity of TOR pro- 
teins. 
A model that explains the dual functions of the kinase 
domain in TOR2 is shown in Figure 7. Distinct effecters 
for the Gl and essential functions of TOR2 may associate 
with separate domains of TOR2. We propose that the Gl 
effector binds to the C-terminal conserved domain, while 
the effector for the essential function binds to the unique 
N-terminal domain. Presumably, the Gl effector is able 
to bind to the same region of the TORl protein. The ef- 
fectors may be involved in localization, where a thus far 
hidden TOR2 lipid kinase activity could be envisioned, 
may be modulated by a phospholipid and/or adenine nu- 
cleotide complex involving the kinase domain, in analogy 
to guanine nucleotide complexes of guanine nucleotide- 
binding proteins, or most simply may be a substrate for a 
Figure 7. A Model of TOR Proteins and Their Functions 
The TOR2 protein has at least two functions that require an intact 
kinase domain. Only its Gi function is sensitive to rapamycin. We 
propose that FKSPIP-rapamycin interferes with the association or 
phosphorylation of a Gi effector of both TORl and TOR2, but not 
an effector of the essential function of TOR2. 
protein kinase activity in TOR2. Since FKBPl2-rapamycin 
does not appear to inhibit the catalytic activity of the kinase 
of TOR2 in a general way, it may instead selectively pre- 
vent the Gl effector from binding to or being phosphory- 
lated by TOR2. 
TOR proteins and their mammalian FRAP homologs me- 
diate mitogenic signaling pathways distinct from the Ras- 
MAPK and, in mammalian cells, Jak-Stat pathways. The 
present work reveals that TORl and TOR2 are complex, 
multidomainal proteins that use their kinase activities to 
effect multiple cell cycle functions, and it provides insights 
into the mechanism by which FKBPlP-rapamycin inhibits 
Gl cell cycle progression. 
Experlmental Procedures 
Yeast Strains and Genetlc Methods 
Standard procedures for culturing and mating strains, diploid isolation, 
sporulation, and tetrad analyses were used (Guthrie and Fink, 1991). 
S. cerevisiae strains used in this study are listed in Table 2. The two 
yeast haploid strains carrying the Ser-1972+Arg mutation in TORf 
and Ser-1975+Arg mutation in TOR2, respectively, were derived from 
YFKO07 (Briruela et al., 1991) by integrating an approximately 900 
bp PCR products containing either Ser-1972eArg (AGC to AGG) in 
7OR7 or Ser-1975+Arg (AGT to AGG) in TOR2. These were confirmed 
by sequencing. An HO gene in pOLl6 was used to construct wild-type 
or homozygous mutant diploid YFKOO7 yeast strains from correspond- 
ing haploid yeast strains. 
Away for TOR I Memctkms wlth FKBP12-Ftapamycln 
To purify yeast FRB proteins from yeast S. cerevisiae, approximately 
0.5 lb of baker’s yeast was lysed with glass beads in TSSN+ (50 mM 
Tris-HCI, 150 mM NaCI, 5 mM NaF, 1 mM N&VO,, 1 @ml leupeptin, 
1 @ml aprotinin, 1 &ml trypsin inhibitor, 1 mM PMSF. 1 mM DlT, 
1% NP40 (pH 7.5)). Lysates were cleared twice by centrifugation for 
30 min at 25,000 x g at 4OC. The pH of the supernatant was adjusted 
to 7.5 with 1 N NaOH. The lysate was then loaded onto a Mono Q 
column. After extensive washing with TBSN+, the bound material was 
eluted with 1 M NaCl TSSN+ and the eluant was equally divided into 
three fractions, each of which was incubated with 0.7 PM yGFK alone, 
yGFK-FK505, or yGFK-rapamycin for 15 min at 4X and loaded onto 
glutathione SSepharose cdumn (GTS, Soehringer). After washed 
with 1 M NaCl TBSN+ extensively, the GTS-bound material was eluted 
into 2 x protein gel sample buffer, separated on SDS-polyacrylamide 
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Table 2. S. cerevisiae Strains 
Strain Genotype Source 
BJ5459 MATa ura3-52 trpl lys2-801 leu2Al his3A20 can1 pep4::his3 prblAl.GR B. Jones 
EdY46 MATa ura3 his3 Wp3 LEXAop-leu2 E. Golemis 
NKY260 MATafa ura3/ura3 leu2Neu2 N. Kleckner 
YFKO07 MATa ads101 lewd1 lys2-801 tfpA1 ura3-52 S. Parent 
YFKlSR MATa ad+101 /e&Al IysZ-801 @-Al ura3-52 TORl (Ser-1972+Arg) This study 
YFK2SR MATa ade-107 /e&Al /ysZ-801 @-Al ura3-52 TOR2 (Ser-1975+Arg) This study 
dYFKOO7 MATa/a ads101 /e&Al 1~~2-801 trp-Al ura3-52 TORlfTORl This study 
dYFK1 SR MATa/a ade701 lewd1 lys2-801 trpdl ura352 TORl (Ser-1972-Arg)/TORl (Ser-1972eArg) This study 
YFKtorlA MATa ade-101 leu-Al Iys2-801 trp-Al ura3-52 torlA::LEU2 This study 
dYFKtor2A MATaIa ada- lewd1 lys2-801 &p-Al ura3-52 TORVTORl tor2A/TORZ This study 
dYFKlSRtor2A MATa/a a&l01 lewd1 /ysZ-801 trpA7 ura3-52 TORl (Ser-1972-ArgyTORI (Ser-1972+Arg) torZA/TORZ This study 
YMWl MATa, ade2-1 ade-3(A22) his3-11,15 /eu2-3,112 trpl-1 can-100 wra3-1 M. Walhberg 
gel, and analyzed by silver staining and by immunoblotting with anti- 
TORI antiserum or preimmune serum. For analyses of mutant TOR 
proteins, 2 litersof YFKO07, YFKl SR, and YFK2SR. respectively, were 
grown to saturation in YPD. Cells were harvested, and the binding 
assays were performed as described above. 
To map regions of TORI necessary for binding to FKBP12-rapa- 
mycin, TORl cDNA corresponding to residues 1100-2470 was sub- 
cloned into pBluescript SK-EE vector, in which TORl is fused in frame 
to a Glu-Glu epitope. The resulting plasmid was digested with the 
following restriction enzymes (the number indicates the last amino 
acid residue of the translation products): Smal (2470). Aatll (2441), 
Aflll(2303), Bglll(2257), EcoRV (2157), Hindlll(2036), BamHl(1660), 
and was used directly for in vitro transcription/translation in rabbit 
reticulocyte lysates to prepare “S-labeled TORl deletion mutant pro- 
teins. The%-labeled TORl proteinswere incubated with 0.7 pM yGFK 
alone, yGFK-FK506, or yGFK-rapamycin for 15 min at 4%. diluted 
50 times into ice-cold TN buffer (50 mM Tris, 1 M NaCl [pH 8.0]), and 
loaded onto a GTS column. After washing with ice-cold TN buffer 
extensively, the GTS-bound materials were eluted into 2 x protein gel 
sample buffer, separated on SDS-polyacrylamide gel, and analyzed 
by autoradiography. TOR1-45 (residues 1766-2159) was generated 
with the following pair of primers by PCR with PFU DNA polymerase 
(Stratagene) from plasmids containing wild-type or TORl mutants at 
Ser-1972 as templates: 5’-CG GGA TCC GCC ATG GTT CAG GAA 
GAG ACT-3’ and 5°C CGA ATT CTA GAT ATC CAA ATG TCT CTT 
GAA-3’. The amplified DNAs were subcloned into pETSa. This plasmid 
was then linearized with EcoRl and used for in vitro transcription. 
Isolation of TORI and TOR2 Genes from S. -revMae 
A genomic DNA library was constructed in pRS315 from a spontane- 
ous dominant rapamycin-resistant yeast mutant and was introduced 
into a wild-type, rapamycin-sensitive yeast strain. A plasmid that con- 
ferred resistance to 100 nM rapamycin was recovered and found to 
be identical to the TOR7 gene, except with a mutation converting Ser- 
1972 to isoleucine. The corresponding wild-type TOR7 gene was iso- 
lated by gap repair of Bgllltut plasmid in wild-type yeast. The TOR2 
genes were isolated similarly. To introduce a convenient restriction 
site for subcloning, the wild-type and mutant TORl plasmids were 
replaced at the 5’ end with a Sacl site followed by the second amino 
acid of TORl using PCR with the following pair of primers: 5%AG 
CTC TTG AAC CGC ATG AGG AGC AGA TIT GG-3’ and 5”ACG GGG 
CCC AAG GGA ACT GCC-3’. The PCR product was digested with 
Sacl-Spel and was used to replace the same restriction fragment of 
the original genomic clones. 
Immunological Techniques 
To generate TORl-specific antiserum, the GST-TORl (1223-2361) 
was expressed as inclusion bodies, purified conveniently by washing 
the cell pellets after lysis, and injected into rabbits. After boosting twice 
with antigens, the antisera tested positive for TORl on a Western blot. 
Western blot analyses were carried out as decribed previously (Harlow 
and Lane, 1966). Antigens were detected using the ECL method (Amer- 
sham). The anti-TORl serum was used at a dilution of 1 :lOOO. The 
anti-flu hemaglutinin monoclonal antibody, MAb 12CA5, was used at 
1:300 dilution. For immunoprecipitation, cell lysates were incubated 
with MAb 120% antibody at a dilution of 1300 for 1 hr at 4%. The 
immunocomplexes were captured with protein G-conjugated Sepha- 
rose by incubating for another hour at 4%, washed three times with 
TBSN+, and three times with TBS plus 1 mM DlT. The final immuno- 
precipitates were either directly used for in vitro kinase assays, or 
were eluted into SDS protein sample buffer for Western blot analyses. 
TORT Expresslon Plasmld Constructs and 
In Vltro Mutagenesis 
To create a galactose-inducible yeast expression vector, the G6PD 
promoter region of pG-1 (2 NM, TRP) (Schena et al., 1991)was inserted 
into the BamHl site with the following oligo sequence encoding an 5’ 
HA epitope: 5’-T ACC ATG GGA TAC CCA TAC GAT GlT CCA GAT 
TAC GCT TGG TAC CAT GGA GCT CGA GTC GAC GGA C-3’ and 
5°C GTC GAC TCG AGC TCC ATG GTA CCA AGC GTA ATC TGG 
AAC ATC GTA TGG GTA TCC CAT GGT AGA TC-3’. The Smal-Sacl 
fragment containing the G6PD promoter of the HA epitope-modified 
pG1 was replaced with a Xhol (blunted)-Sacl fragment containing the 
GAL70 promoter from YCPIFI 5. The full-length TORl was then cloned 
into this expression vector with a HA tag on its immediate 5’ end. 
To introduce mutations at Ser-1972, the Sacll-Kpnl fragment of 
TORl was subcloned into pBluescript SK(+) (Stratagene) (pBluescript 
TORlSK). In vitro phagemid mutagenesis was carried out with the 
following primers: Ser-1972-Ala, 5’-ATGTTCAACGAGCG- 
GGCCGCATClTCCAGTCCTTCA-3’; Ser-1972+Glu, 5’ATGTTCAA- - 
CGAAAAATTGGCGlTCCGCATCTTCCAGTCClTC-3’; Ser-1972- 
Arg, 5’-GlTCAACGAAAAA~GGCG~CTCGCATCITCCAGTCCT-3’. 
The mutant DNA was inserted back into the full-length TORl gene by 
subcloning the Ncol-Kpnl mutant fragment into the HA-tagged TORl 
construct. To introduce kinase inactivation mutations into TORl, the 
Kpnl-Sall fragment of TORl was subcloned into pBluescript KS(+). 
In vitro mutagenesis was carried out as above with the following prim- 
ers: Arg-2276+Pro, S’CTGGGACTAGGTGATC~CCATCCAAGCAA- 
CCTG-3’; Asp2294+Glu, 5%lTATCCACATTGA&lXGGCGAlTG- 
lllTGA-3’. To reconstruct the full-length Arg-2276 and the Asp-2294 
mutant TORl gene, the Kpnl-Sall DNA fragments from the TOR7 mu- 
tant mutagenesis constructs were excised, purified, and subcloned 
back into the HA-tagged wild-type or mutant TOR7. All mutations were 
confirmed by DNA sequencing. 
To construct TOR2-TORl mutants, the BamHI-Pstl fragment of 
wild-type and mutant TORl, which contains codons 1661-2470 and 
the 3’-noncoding sequences of TORl, were excised from the above 
TORl expression construct and fused with a TOR2 genomic DNA con- 
taining the upstream promoter region and codons 1-1666 in pRS315. 
The TORl-45 wild-type and mutant DNA fragments were subcloned 
into the BamHI-EcoRI sites of pYES (2 PM, GALl) (Invitrogen). 
Testing Growth PropertIes of Yeast Strains 
To test the growth of yeast strains on plates, freshly grown yeast colo- 
nies were streaked onto selection plates containing either glucose 
or galactose in the presence or absence of 100 nM rapamycin and 
incubated for 3-4 days at 30%. To test the growth of yeast strains 
in liquid culture, yeast cells were first grown overnight in glucose selec- 
tion medium, diluted into YP-sucrose medium at OD, = 0.25, and 
incubated for 2 hr at 30%. Cells were pelleted and resuspended into 
YP-galactose medium. Cells were incubated at 30% with shaking. 
Aliquots of 1 ml culture were drawn at different times for OD measure- 
ments at 800 nM. 
TORI and TOR2 Dlaruptlona 
The TORI disruption vector was constructed by inserting the Bglll- 
Sglll fragment from YEpl3 containing the LEM selection marker gene 
into the BamHl site of TORI in pBluescript TORlSK. The gene disrup- 
tion construct was linearized and transform into haploid YKFOO7 
strain selecting for leucine (tor7::LEf.Q) prototrophy. The disruption of 
the TORI locus was confirmed by PCR analyses of genomic DNA 
prepared from these LEU2’clones with one TORI primer (5’-AAC GCC 
AGA GAT lTG CTT GTGS’) and with one LEU2 primer (5’-GAT ClT 
Cl-T AGG GGC AGA CAT-3’). 
The Sphl-Smal fragment of TOR2 was subcloned into pTZl8 (Sio- 
Rad) vector to give pTz-TOR2SS. The TOR2 disruption vector was 
constructed by inserting eitherthe same Bglll-Bglll fragment of aLEU2 
marker gene as above, or a Bglll-BamHI fragment that contains a 
HEG-URA-HISG marker gene cassette from PNKY51 into the SamHl 
site of TOR2. The LEU2 disruption plasmid was linearized and trans- 
formed into diploid wild-type YFKoO7 (MATa/a TORI/TOR1) or homo- 
zygous TORI (Ser-1972*Arg) mutant (MATala TORI [Ser-1972+Argy 
TOR7 [Ser-1972+Arg]) selecting for leucine or uracil prototrophies. 
The HI.%&URA-HISG disruption construct was linearized and intro- 
duced into a diploid strain NKY260. The heterozygous disruption of 
the 7OR2locus wasconfirmed by PCRanalysesofthe TOR2disruption 
with one TOR2 primer @‘-GAG GTA GAA lTC lTA GAA GAGS’), one 
EU2 primer (5%AT CIT ClT AGG GGC AGA CATJ’), or one HlSG 
primer (6’-TAA GCG GOT GGT GTC TAA CAT-3’). Diploid strains het- 
erozygous for TOR2 disruption were sporulated by patching yeast cells 
onto sporulation medium and incubating at room temperature and 
were dissected on YPD. After viable spores formed colonies on YPD 
plates, replica plates were made with synthetic medium for testing 
cosegregation of the selective markers. 
Complementation of the Temperature Sensitivity 
of a forf Mutant Strain 
A Xhol-SamHI fragment (nucleotides 1289-2473) and Sacll-SamHI 
fragment (nucleotides 39016348) of TORI were cloned in a three 
part ligation into pRS304 (Sikorski and Hieter, 1989) to create pYDF79. 
pYDF79 was linearized with BamHl and transformed into YMWl (M. 
Wahlberg, University of Texas Southwestern). A transformant was 
picked for Southern blot analysis to confirm that it does contain a tori 
deletion. This mutant grows about 80% as fast as the wild-type strain 
at 24% and 30% but is arrested at 37% 
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